Evidence map›Paper›PMID 25049417›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

PAPD5-mediated 3' adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease.

Joost Boele, Helena Persson, Jay W Shin, Yuri Ishizu, Inga S Newie, Rolf Søkilde, Shannon M Hawkins, Cristian Coarfa, Kazuhiro Ikeda, Ken-ichi Takayama and 19 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The biogenesis and regulation of animal microRNAs.Nature reviews. Molecular cell biology · 2025
    Review
  10. Review
  11. ncRNA Editing: Functional Characterization and Computational Resources.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  12. Article
  13. Oncofetal IGF2BP3-mediated control of microRNA structural diversity in the malignancy of early-stage lung adenocarcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 12 institutions in 5 countries.

Joost BoeleRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Department of Systems Bioinformatics, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam, 1081 HV, Amsterdam, The Netherlands;ORCID http://orcid.org/0000-0002-7183-9650
Helena PerssonDepartment of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden;
Jay W ShinRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Yuri IshizuRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Inga S NewieDivision of Oncology, Department of Clinical Sciences, Lund University Cancer Center/Medicon Village, SE-223 81 Lund, Sweden;
Rolf SøkildeDivision of Oncology, Department of Clinical Sciences, Lund University Cancer Center/Medicon Village, SE-223 81 Lund, Sweden;
Shannon M HawkinsDepartment of Obstetrics and Gynecology and Center for Reproductive Medicine.
Cristian CoarfaDepartment of Molecular and Cellular Biology, and.
Kazuhiro IkedaDivision of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama 350-1241, Japan;
Ken-ichi TakayamaDepartments of Anti-Aging Medicine andGeriatric Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan;
Kuniko Horie-InoueDivision of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama 350-1241, Japan;
Yoshinari AndoRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD 21205;
A Maxwell BurroughsRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894;
Chihiro SasakiRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;
Chizuru SuzukiRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;
Mizuho SakaiRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Shintaro AokiRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Ayumi OgawaRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;
Akira HasegawaRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Marina LizioRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Kaoru KaidaRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Bas TeusinkDepartment of Systems Bioinformatics, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam, 1081 HV, Amsterdam, The Netherlands;
Piero CarninciRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Harukazu SuzukiRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan;
Satoshi InoueDivision of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama 350-1241, Japan;Departments of Anti-Aging Medicine andGeriatric Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan;
Preethi H GunaratneDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030;Department of Biology and Biochemistry, University of Houston, Houston, TX 77204; and.
Carlos RoviraDivision of Oncology, Department of Clinical Sciences, Lund University Cancer Center/Medicon Village, SE-223 81 Lund, Sweden;
Yoshihide HayashizakiRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;RIKEN Preventive Medicine and Diagnosis Innovation Program, Wako, Saitama 351-0198, Japan.
Michiel J L de HoonRIKEN Omics Science Center, Yokohama, Kanagawa 230-0045, Japan;Division of Genomic Technologies, RIKEN Center for Life Science Technologies, Yokohama, Kanagawa 230-0045, Japan; mdehoon@gsc.riken.jp.
RIKEN Center for Integrative Medical Sciences · JPSaitama Medical University · JPMedicon Village · SEBaylor College of Medicine · USInstitut de Médecine de la Reproduction · FRJohns Hopkins University · USKarolinska Institutet · SELund University · SENational Center for Biotechnology Information · USRIKEN · JPThe University of Tokyo · JPVrije Universiteit Amsterdam · NL

Funding

TRANSGENIC MOUSE MODELS TO STUDY OVARIAN FUNCTIONU54HD007495 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI RICHARDS, JOANNE STEWART · 1998 to 2013
$19.9M
NICHD NIH HHS U54 HD007495NICHD NIH HHS U54HD007495
6 · The paper itself

Abstract

Next-generation sequencing experiments have shown that microRNAs (miRNAs) are expressed in many different isoforms (isomiRs), whose biological relevance is often unclear. We found that mature miR-21, the most widely researched miRNA because of its importance in human disease, is produced in two prevalent isomiR forms that differ by 1 nt at their 3' end, and moreover that the 3' end of miR-21 is posttranscriptionally adenylated by the noncanonical poly(A) polymerase PAPD5. PAPD5 knockdown caused an increase in the miR-21 expression level, suggesting that PAPD5-mediated adenylation of miR-21 leads to its degradation. Exoribonuclease knockdown experiments followed by small-RNA sequencing suggested that PARN degrades miR-21 in the 3'-to-5' direction. In accordance with this model, microarray expression profiling demonstrated that PAPD5 knockdown results in a down-regulation of miR-21 target mRNAs. We found that disruption of the miR-21 adenylation and degradation pathway is a general feature in tumors across a wide range of tissues, as evidenced by data from The Cancer Genome Atlas, as well as in the noncancerous proliferative disease psoriasis. We conclude that PAPD5 and PARN mediate degradation of oncogenic miRNA miR-21 through a tailing and trimming process, and that this pathway is disrupted in cancer and other proliferative diseases.

Indexed as

RNA StabilityAdenineBase SequenceCytosineExoribonucleasesGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHigh-Throughput Nucleotide SequencingHumansMCF-7 CellsMicroRNAsModels, BiologicalMolecular Sequence DataNeoplasmsNucleic Acid ConformationAdenineCytosineExoribonucleasesMicroRNAsMIRN21 microRNA, humanProtein IsoformsRibonuclease IIIRNA NucleotidyltransferasesTENT4B protein, humanmicroRNA processingnucleotidyl transferase

Identifiers

PMID25049417
PMCPMC4128123
OpenAlexW2053841327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.